ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Normative Modeling of Amygdala Subfields and Disease-Specific Vulnerabilities Across Neurological Disorders.Neuroscience bulletin · 2026Article
- Sex Differences in the Neuropsychiatric Symptoms of Multiple Sclerosis: Symptômes neuropsychiatriques de la sclérose en plaques: différences selon le sexe.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Article
- Depression as a Disease of White Matter Network Disruption: Learning From Multiple Sclerosis.Biological psychiatry · 2026Review
- Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.Neurology · 2026Article
- Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.Journal of neurology · 2026Article
- Affective reserve in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Short-term changes in objectively measured activity predict brain atrophy and disability progression in multiple sclerosis.medRxiv : the preprint server for health sciences · 2025Article
- Evidence of symptom specificity for depression in multiple sclerosis: A two sample Mendelian randomization study.Multiple sclerosis and related disorders · 2024Article
- Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundConsistent findings on underlying brain features or specific structural atrophy patterns contributing to depression in multiple sclerosis (MS) are limited.
objectiveTo investigate how deep gray matter (DGM) features predict depressive symptom trajectories in MS patients.
methodsWe used data from the MS Partners Advancing Technology and Health Solutions (MS PATHS) network in which standardized patient information and outcomes are collected. We performed whole-brain segmentation using SLANT-CRUISE. We assessed if DGM structures were associated with elevated depressive symptoms over follow-up and with depressive symptom phenotypes.
resultsWe included 3844 participants (average age: 46.05 ± 11.83 years; 72.7% female) of whom 1905 (49.5%) experienced ⩾1 periods of elevated depressive symptoms over 2.6 ± 0.9 years mean follow-up. Higher caudate, putamen, accumbens, ventral diencephalon, thalamus, and amygdala volumes were associated with lower odds of elevated depressive symptoms over follow-up (odds ratio (OR) range per 1
conclusionLower DGM volumes were associated with depressive symptom trajectories in MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.